Introgen Therapeutics, Inc.'s p53 Immunotherapy Drug Candidate to Advance Into Second Phase 2 Clinical Trial in Small Cell Lung Cancer With National Cancer Institute

AUSTIN, Texas & TAMPA, Florida--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) and Moffitt Cancer Center today announced plans to begin a phase 2 randomized, controlled study of INGN 225, Introgen’s investigational immunotherapy product in patients with metastatic small-cell lung cancer (termed extensive stage SCLC).